This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Heart Failure or Endothelium
and you are
between 18 and 80
years old
Phase
-
The phase for this study is not defined.
Show me locations

The purpose

Despite modern advances in treatment, heart failure continues to carry a poor prognosis with high morbidity and mortality rates. Hence, there remains a major interest in the development of novel therapeutic agents for this debilitating condition. Urocortins have recently shot into limelight with their potential role in the pathophysiology and treatment of heart failure. Recent studies by the investigators group (REC no: 09/S1103/41) have confirmed that Urocortin 2 and 3 are potent arterial vasodilators, the effects of which are reproducible and well tolerated in healthy male volunteers. Previous studies using heart failure models in animals1-7, as well studies in heart failure patients (Urocortin 2), suggest that there is great scope for Urocortins as novel biomarkers and as potential therapeutic agents in heart failure. With this in mind, the investigators wish to study the local vasomotor effects of these peptides in greater detail in patients with heart failure.

Provided treatments

  • Drug: Urocortin 2, Urocortin 3 and Substance P
Tris trial is registered with FDA with number: NCT01599728. The sponsor of the trial is University of Edinburgh and it is looking for 22 volunteers for the current phase.
Official trial title:
Urocortins 2 & 3-Effects on Forearm Arterial Blood Flow in Patients With Heart Failure